Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC

The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2017-06, Vol.37 (6), p.3189
Main Authors: Mencoboni, Manlio, Filiberti, Rosa Angela, Taveggia, Paola, Del Corso, Lisette, Del Conte, Alessandro, Covesnon, Maria Grazia, Puccetti, Cheti, Donati, Sara, Auriati, Laura, Amoroso, Domenico, Camerini, Andrea
Format: Article
Language:English
Subjects:
Administration, Metronomic
Administration, Oral
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - adverse effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Disease-Free Survival
Feasibility Studies
Female
Humans
Italy
Kaplan-Meier Estimate
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Medication Adherence
Pilot Projects
Time Factors
Treatment Outcome
Vinblastine - administration & dosage
Vinblastine - adverse effects
Vinblastine - analogs & derivatives
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points. Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%. Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea. Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.11679